Orthonotes
Orthonotes
by the.bonestories
v3.0 Fusion
v3.0 Fusion
general topic hub

Osteoporosis — Pathophysiology and Management

Definition (WHO): low bone mass with microarchitectural deterioration → fragility fractures; T‑score ≤ −2.5 on DEXA. Common sites: vertebral compression, hip (femoral neck/intertrochanteric), distal radius. Risk factors: age, female sex, postmenopausal status, low BMI, glucocorticoids, smoking/alcohol, endocrine/renal disease. Workup: DEXA (hip/spine), FRAX (10‑yr risk), labs to exclude secondary causes (Ca, PO4, ALP, 25‑OH Vit D, TSH, PTH, renal/liver). Treatment: lifestyle (Ca 1000–1200 mg; Vit D 800–1000 IU; resistance/balance exercise; fall prevention); pharmacotherapy for T ≤ −2.5 or prior fragility fracture or high FRAX. Pharmacology: bisphosphonates (alendronate, risedronate, zoledronate), denosumab, anabolic agents (teriparatide/abaloparatide; romosozumab), SERMs (raloxifene) in selected women. Monitoring: repeat DEXA 1–2 years; drug holidays after 3–5 yrs oral/3 yrs IV bisphosphonate in low‑risk; continue in high‑risk. Complications & prevention: vertebral kyphosis, hip fracture morbidity/mortality; hip protectors, home safety, vision correction.

Overview

Topic summary

View wiki
Definition (WHO): low bone mass with microarchitectural deterioration → fragility fractures; T‑score ≤ −2.5 on DEXA. Common sites: vertebral compression, hip (femoral neck/intertrochanteric), distal radius. Risk factors: age, female sex, postmenopausal status, low BMI, glucocorticoids, smoking/alcohol, endocrine/renal disease. Workup: DEXA (hip/spine), FRAX (10‑yr risk), labs to exclude secondary causes (Ca, PO4, ALP, 25‑OH Vit D, TSH, PTH, renal/liver). Treatment: lifestyle (Ca 1000–1200 mg; Vit D 800–1000 IU; resistance/balance exercise; fall prevention); pharmacotherapy for T ≤ −2.5 or prior fragility fracture or high FRAX. Pharmacology: bisphosphonates (alendronate, risedronate, zoledronate), denosumab, anabolic agents (teriparatide/abaloparatide; romosozumab), SERMs (raloxifene) in selected women. Monitoring: repeat DEXA 1–2 years; drug holidays after 3–5 yrs oral/3 yrs IV bisphosphonate in low‑risk; continue in high‑risk. Complications & prevention: vertebral kyphosis, hip fracture morbidity/mortality; hip protectors, home safety, vision correction.
Cases

Clinical case discussions

Browse all cases
MCQs

High-yield practice questions

Start topic quiz
Question 1

What is the WHO definition of osteoporosis based on DEXA T-score?

Question 2

Which of the following is NOT a common site for fragility fractures in osteoporosis?

Question 3

Which of the following is a key risk factor for developing osteoporosis?

Question 4

What is the purpose of the FRAX tool in osteoporosis management?

Question 5

Which medication class is primarily used for the pharmacological management of osteoporosis?

Question 6

What is the recommended daily intake of Vitamin D for the management of osteoporosis in adults?

Question 7

When should a repeat DEXA scan be performed in patients with osteoporosis?

Question 8

What lifestyle modification is recommended to prevent further fractures in osteoporosis patients?

Question 9

Which of the following complications is commonly associated with osteoporosis?

Question 10

Which of the following treatments is considered an anabolic agent for osteoporosis?